Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APLT NASDAQ:APRE NASDAQ:KNSA NASDAQ:PHAT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLTApplied Therapeutics$0.10$0.10$0.09▼$1.50$15.86M2.087.28 million shsN/AAPREAprea Therapeutics$0.69$0.85$0.55▼$2.22$8.49M1.51136,735 shs383,724 shsKNSAKiniksa Pharmaceuticals International$51.89$50.50$26.27▼$59.87$3.99B0.12506,065 shs362,761 shsPHATPhathom Pharmaceuticals$10.37$11.52$7.61▼$18.31$827.11M0.511.07 million shs554,284 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLTApplied Therapeutics0.00%0.00%0.00%+0.00%-70.90%APREAprea Therapeutics0.00%-7.46%-26.23%-9.26%-63.70%KNSAKiniksa Pharmaceuticals International0.00%+7.17%-8.18%+11.59%+83.36%PHATPhathom Pharmaceuticals0.00%+2.37%-12.64%-0.67%-2.54%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLTApplied Therapeutics$0.10$0.10$0.09▼$1.50$15.86M2.087.28 million shsN/AAPREAprea Therapeutics$0.69$0.85$0.55▼$2.22$8.49M1.51136,735 shs383,724 shsKNSAKiniksa Pharmaceuticals International$51.89$50.50$26.27▼$59.87$3.99B0.12506,065 shs362,761 shsPHATPhathom Pharmaceuticals$10.37$11.52$7.61▼$18.31$827.11M0.511.07 million shs554,284 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLTApplied Therapeutics0.00%0.00%0.00%+0.00%-70.90%APREAprea Therapeutics0.00%-7.46%-26.23%-9.26%-63.70%KNSAKiniksa Pharmaceuticals International0.00%+7.17%-8.18%+11.59%+83.36%PHATPhathom Pharmaceuticals0.00%+2.37%-12.64%-0.67%-2.54%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPLTApplied Therapeutics 1.67Reduce$1.00870.87% UpsideAPREAprea Therapeutics 2.40Hold$4.07492.72% UpsideKNSAKiniksa Pharmaceuticals International 2.89Moderate Buy$60.8617.28% UpsidePHATPhathom Pharmaceuticals 2.86Moderate Buy$24.50136.26% UpsideCurrent Analyst Ratings BreakdownLatest KNSA, APRE, PHAT, and APLT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/8/2026KNSAKiniksa Pharmaceuticals International Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C+) ➝ Buy (B-)5/18/2026KNSAKiniksa Pharmaceuticals International Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/14/2026APREAprea Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$7.00 ➝ $6.005/7/2026APREAprea Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$5.005/6/2026KNSAKiniksa Pharmaceuticals International Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C) ➝ Hold (C+)4/29/2026KNSAKiniksa Pharmaceuticals International Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$62.00 ➝ $64.004/29/2026KNSAKiniksa Pharmaceuticals International CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$50.00 ➝ $60.004/29/2026KNSAKiniksa Pharmaceuticals International WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$58.00 ➝ $59.004/29/2026KNSAKiniksa Pharmaceuticals International Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$53.00 ➝ $57.004/28/2026KNSAKiniksa Pharmaceuticals International Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$58.00 ➝ $71.004/21/2026KNSAKiniksa Pharmaceuticals International Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)(Data available from 6/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPLTApplied Therapeutics$1M15.86N/AN/A$0.49 per share0.21APREAprea Therapeutics$290K29.29N/AN/A$1.52 per share0.45KNSAKiniksa Pharmaceuticals International$677.56M5.89$0.79 per share65.37$7.44 per share6.97PHATPhathom Pharmaceuticals$175.11M4.72N/AN/A($6.14) per share-1.69Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPLTApplied Therapeutics-$105.62M-$0.10N/AN/AN/AN/A-340.84%-175.00%N/AAPREAprea Therapeutics-$12.60M-$1.54N/AN/AN/A-4,405.59%-61.03%-50.24%8/11/2026 (Estimated)KNSAKiniksa Pharmaceuticals International$59.01M$0.9057.6630.52N/A9.69%13.26%9.86%7/28/2026 (Estimated)PHATPhathom Pharmaceuticals-$221.25M-$2.12N/A6.65N/A-76.77%N/A-44.29%8/6/2026 (Estimated)Latest KNSA, APRE, PHAT, and APLT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026APREAprea Therapeutics-$0.23-$0.22+$0.01-$0.22$0.00 million$0.28 million4/28/2026Q1 2026KNSAKiniksa Pharmaceuticals International$0.18$0.27+$0.09$0.27$206.11 million$214.27 million3/16/2026Q4 2025APREAprea Therapeutics-$0.38-$0.32+$0.06-$0.32N/A$0.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPLTApplied TherapeuticsN/AN/AN/AN/AN/AAPREAprea TherapeuticsN/AN/AN/AN/AN/AKNSAKiniksa Pharmaceuticals InternationalN/AN/AN/AN/AN/APHATPhathom PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPLTApplied TherapeuticsN/A0.960.96APREAprea TherapeuticsN/A8.928.92KNSAKiniksa Pharmaceuticals InternationalN/A3.793.33PHATPhathom PharmaceuticalsN/A2.212.16Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPLTApplied Therapeutics98.31%APREAprea Therapeutics34.19%KNSAKiniksa Pharmaceuticals International53.95%PHATPhathom Pharmaceuticals99.01%Insider OwnershipCompanyInsider OwnershipAPLTApplied Therapeutics1.60%APREAprea Therapeutics10.49%KNSAKiniksa Pharmaceuticals International51.98%PHATPhathom Pharmaceuticals9.33%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPLTApplied Therapeutics30153.96 million151.50 millionOptionableAPREAprea Therapeutics712.38 million11.08 millionNo DataKNSAKiniksa Pharmaceuticals International22076.94 million36.95 millionOptionablePHATPhathom Pharmaceuticals11079.76 million72.32 millionOptionableKNSA, APRE, PHAT, and APLT HeadlinesRecent News About These CompaniesPhathom Pharmaceuticals, Inc. (PHAT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 9, 2026 | seekingalpha.comPhathom: Why I'm Downgrading To "Sell" Ahead Of CompetitionJune 9, 2026 | seekingalpha.comComparing Phathom Pharmaceuticals (NASDAQ:PHAT) & INmune Bio (NASDAQ:INMB)June 8, 2026 | americanbankingnews.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Consensus Rating of "Moderate Buy" by BrokeragesJune 8, 2026 | americanbankingnews.comPhathom Pharmaceuticals (PHAT) Receives a Buy from BarclaysMay 24, 2026 | theglobeandmail.comPhathom Pharmaceuticals to Participate in Upcoming Investor ConferencesMay 22, 2026 | globenewswire.comPhathom Pharmaceuticals Inc Ordinary shares PHATMay 21, 2026 | morningstar.comMPhathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual MeetingMay 20, 2026 | globenewswire.comWhy Phathom Pharmaceuticals, Inc.’s (PHAT) Stock Is Down 6.78%May 17, 2026 | aaii.comAPhathom Pharmaceuticals Signals Strong Growth on Earnings CallMay 16, 2026 | theglobeandmail.comPhathom Pharmaceuticals Announces $130 Million Public OfferingMay 12, 2026 | theglobeandmail.comPhathom Pharmaceuticals (PHAT) Is Up 11.0% After Narrowing Q1 Loss And Reaffirming 2026 Profitability TimelineMay 5, 2026 | finance.yahoo.comHow The Phathom Pharmaceuticals (PHAT) Narrative Is Shifting Around Profitability And Exclusivity RisksMay 5, 2026 | finance.yahoo.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Phathom Pharmaceuticals (PHAT), TELA Bio (TELA) and Nanobiotix (NBTX)May 2, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Amgen (AMGN), Phathom Pharmaceuticals (PHAT) and Zimmer Biomet Holdings (ZBH)May 2, 2026 | theglobeandmail.comPhathom Pharmaceuticals, Inc. Q1 2026 Earnings Call SummaryMay 2, 2026 | finance.yahoo.comPhathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual MeetingMay 1, 2026 | globenewswire.comPhathom Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call PresentationApril 30, 2026 | seekingalpha.comPhathom Pharmaceuticals, Inc. (PHAT) Q1 2026 Earnings Call TranscriptApril 30, 2026 | seekingalpha.comPhathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue EstimatesApril 30, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 20263 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPOBy Ryan Hasson | May 20, 2026Kiniksa Pharmaceuticals Still Has Room to Run After 100% RallyBy Chris Markoch | May 23, 2026KNSA, APRE, PHAT, and APLT Company DescriptionsApplied Therapeutics NASDAQ:APLT$0.10 0.00 (0.00%) As of 06/12/2026Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.Aprea Therapeutics NASDAQ:APRE$0.69 0.00 (0.00%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$0.70 +0.02 (+2.75%) As of 06/12/2026 04:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.Kiniksa Pharmaceuticals International NASDAQ:KNSA$51.89 0.00 (0.00%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$51.81 -0.08 (-0.15%) As of 06/12/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.Phathom Pharmaceuticals NASDAQ:PHAT$10.37 0.00 (0.00%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$10.38 +0.01 (+0.10%) As of 06/12/2026 04:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? Alphabet's Most Overlooked Division Just Had a Big Week Robinhood Wants a Bigger Role in IPOs—Here's Why It Matters Viasat's Orbiting Profits: Space Force Jackpot? What to Expect From Q2 Earnings as Tech Strength Broadens ERock IPO: A $1.3B Power Play Solution TJX: Retail’s Apex Predator Feasts on Inflation Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
